Bibliographical noteFunding Information:
This study was funded by the Lillehei Heart Institute High Risk High Reward Grant and American Heart Association Scientist Development Grant 15SDG25560048. Archer is funded by Canada Foundation for Innovation (229252 and 33012), a Tier 1 Canada Research Chair in Mitochondrial Dynamics and Translational Medicine (950-229252), and a grant from the William J Henderson Foundation; Prins is funded by NIH K08 HL140100, the Cardiovascular Medical Research and Education Fund, a Lillehei Heart Institution Cardiovascular Seed Grant, and the United Therapeutics Jenesis Award; and Thenappan is funded by the Cardiovascular Medical Research and Education Fund.
Prins served on an advisory board for Actelion and receives grant funding from United Therapeutics. Thenappan served on an advisory board for Actelion, United Therapeutics, Gilead, Aria CV, and Altvant Science. Thenappan’s institution has received research funding from United Therapeutics, Aria CV, and Tenax Therapeutics for conducting clinical trials. The remaining authors have no disclosures to report.
PubMed: MeSH publication types
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't